A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-12-14

Summary

This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B) a single dose of combined drospirenone and ethinyl estradiol. The study will be conducted in adult participants with advanced malignancies for whom no standard or curative treatment options are available.

• Phase: PHASE1

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: drospirenone; Ethinyl Estradiol; Midazolam; repaglinide